Quarterly report pursuant to Section 13 or 15(d)


9 Months Ended
Sep. 30, 2023
Restructuring and Related Activities [Abstract]  

13. Restructuring

As a result of the Restructuring, the Company incurred $2.4 million in costs for the three and nine months ended September 30, 2023. Restructuring costs were comprised of $2.0 million of severance, post employment benefits, stock-based compensation and outplacement services, and $0.4 million of asset impairment charges related to the laboratory equipment that is classified as assets held for sale.

As of September 30, 2023, $1.8 million of Restructuring costs remain unpaid and are included in the accrued expenses in the Company's condensed consolidated balance sheet. The accrued Restructuring costs are expected to be paid by the end of 2023.